Selecta Biosciences Inc. is a clinical-stage biotechnology company that has merged with Cartesian Therapeutics. The company is pioneering RNA cell therapy to treat autoimmune diseases, leveraging its clinically validated ImmTOR® platform to develop antigen-specific tolerogenic therapies.
Focus Areas
Notable Investments
